Endocrine Abstracts

Background: TPTD treatment has been shown to reduce vertebral and non-vertebral fracture risk in postmenopausal osteoporosis efficiently. However, gains in bone mass achieved by this treatment are almost lost 2 years after cessation of treatment, unless consecutively followed by an antiresorptive treatment such as alendronate.Subjects and methods: In the present prospective randomised open-labelled study in 52 pmp women, we investigated the effect of eit...